We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AZD2816

News List

First patients vaccinated with AstraZeneca’s COVID-19 variant vaccine europeanpharmaceuticalreview
July 05, 2021
The Phase II/III trial will assess the safety and immunogenicity of a AstraZeneca’s novel COVID-19 variant vaccine candidate, AZD2816.
First COVID-19 Variant Vaccine Trial Participants Vaccinated americanpharmaceuticalreview
June 30, 2021
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 have been vaccinated to assess safety and immunogenicity in both previously vaccinated and unvaccinated adults.
AZ doses first participants with COVID-19 variant vaccine pharmatimes
June 29, 2021
AstraZeneca (AZ) has announced that the first participants have been vaccinated as part of a Phase II/III trial testing a new COVID-19 variant vaccine – AZD2816.
First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated firstwordpharma
June 28, 2021
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults.